Product Details
| Product Name:
PD173212 |
CAS No.:
217171-01-2 |
| Purity:
99.54% |
Supply Ability:
10g |
| Release date:
2025/04/28 |
Product Introduction
Bioactivity
| Name | PD173212 |
| Description | PD 173212 is a blocker that blocks N-type voltage sensitive calcium channel (Cav2.2). PD173212 (0.0017-1.7 μmol/kg, Intraperitoneal Injection.) dose-dependently reduced DNBS-induced visceral hypersensitivity in mice. |
| In vitro | PD 173212 blocked recombinant B-class (N-type) Ca+2 channels with a IC50 of 74 nM (N = 2), and blocked Na+ channels by 8% at 1 μM (N = 4), and blocked K+ channels by 10% at 1 μM (N = 4) in superior cervical ganglion neurons. PD 173212 effectively blocks recombinant B-class (N-type) calcium channel currents 78±7.8% (IC50: 74 nM), by whole-cell voltage-clamp techniques[1]. |
| In vivo | This study evaluated the effect of acute administration of the selective N-type Cav2.2 blocker PD17321238 in their visceral pain model. The test (VMR assessment) was performed on day 14 after DNBS injection. PD173212 (0.0017-1.7 μmol·kg?1, i.p.) dose-dependently reduced the visceral hypersensitivity induced by DNBS. The compound started to be effective at a dose of 0.017 μmol·kg?1 and completely relieved abdominal pain when administered at a ten-fold higher dose[2]. In the audiogenic seizure model, PD173212 (30 mg/kg, i.v.) displays moderate efficacy in preventing tonic seizures[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 90 mg/mL (150.04 mM), Sonication is recommended.
|
| Keywords | VSCC | PD-173212 | PD173212 | PD 173212 | N-type Ca2+ channel | CalciumChannel | Calcium Channel |
| Inhibitors Related | Nisoldipine | Diltiazem hydrochloride | Levetiracetam | L-Ascorbic acid | L-Phenylalanine | D-Menthol | Ethyl cinnamate | L-Ascorbic acid sodium salt | 1-Octanol | 2-Nitrobenzoic acid | Nifedipine | Otilonium bromide |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Calcium Channel Compound Library | Neuroprotective Compound Library | Anti-Cardiovascular Disease Compound Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2052128-15-9
$47.00 / 1mg
-
CAS:64544-07-6
$36.00 / 10mg
-
CAS:148707-39-5
$80.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States